Deborah Strahs
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hughes, Brett
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
DESQUAMATE, NCT05025813: Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Recruiting
2
27
RoW
Pembrolizumab, External Beam Radiation Therapy, Radical Neck Dissection
Queensland Health, Merck Sharp & Dohme LLC
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
06/25
06/27
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
Strahs, Deborah
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hughes, Brett
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
DESQUAMATE, NCT05025813: Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Recruiting
2
27
RoW
Pembrolizumab, External Beam Radiation Therapy, Radical Neck Dissection
Queensland Health, Merck Sharp & Dohme LLC
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
06/25
06/27
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
Strahs, Deborah
No trials found

Download Options